EUCTR2004-001729-11-SI进行中（未招募）不适用
A prospective, randomised, placebo controlled, double blind trial about safety and efficacy of combined treatment with Alteplase (rt-PA) and Cerebrolysin in acute ischemic hemispheric stroke - CERE-LYSE-1
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 108
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Female or male inpatients.
- •Age: 18-80 years.
- •If female, patient must not be pregnant
- •Clinical diagnosis of ischemic stroke causing a measurable neurological deficit
- •defined as impairment of language, motor function, cognition and/or gaze,
- •vision or neglect. Ischemic stroke is defined as an event characterised by the
- •sudden onset of an acute focal neurologic deficit presumed to be due to
- •cerebral ischemia after CT scan excludes haemorrhage.
- •Onset of symptoms within 3 hours prior to initiation of rt-PA administration.
- •Stroke symptoms are to be present for at least 30 minutes and have not
- •significantly improved before treatment. Symptoms must be distinguishable from an episode of generalised ischemia (i.e. syncope), seizure or migraine disorder.
- •Patient is willing to participate voluntarily and to sign a written patient
- •informed consent. Informed consent will be obtained from each patient or the
- •subject's legally authorised representative or relatives, or deferred where
- •applicable, according to the regulatory and legal requirements of the
- •participating country.
- •Patients who are unable to sign but who are able to understand the meaning of
- •participation in the study may give an oral witnessed informed consent. These
- •patients have to make clear undoubtfully that they are willing to participate
- •voluntarily and must be able to understand an explanation of the contents of the
- •information sheet. A written consent has to be obtained as soon as possible.
- •Patients who are incapable of giving consent may be included as well. These patients have to sign a written consent as soon as they are able to understand the meaning of participating in the study and are able to sign. The investigator and an independent witness have to sign the informed consent before any study specific procedures are performed. As soon as the patient is recovering, obtaining of oral, physical or written informed consent has to be achieved. If patients are not willing to stay in the study they have to be asked if data obtained so far can be used. This has to be documented on a separate form.
- •Willingness and ability to comply with the protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Evidence of intracranial haemorrhage (ICH) on the CT-scan
- •Participation in another therapeutic clinical trial 3 months before baseline
- •Patients with any history of prior stroke and concomitant diabetes
- •Prior stroke within the last 3 months
- •Platelet count of below 100x103/mm3
- •Blood glucose <50 or >400 mg/dl (<2.77 or >22.15 mmol/L)
- •Known haemorrhagic diathesis
- •Manifest or recent severe or dangerous bleeding
- •Known bacterial endocarditis, pericarditis
- •Acute pancreatitis
- •Documented ulcerative gastrointestinal disease during the last 3 months, oesophageal varices, arterial-aneurysm, arterial/venous malformation
- •Neoplasm with increased bleeding risk
- •Severe liver disease, including hepatic failure, cirrhosis, portal hypertension, oesaphageal varices) and active hepatitis
- •Major surgery or significant trauma in past 3 months
- •Multiple serious drug allergies
- •Hypersensitivity to one of the components of the drug
- •Severe renal impairment
- •Systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg, or aggressive management (IV medication repeatedly) necessary to reduce BP to these limits
- •Recent (less than 10 days) traumatic external heart massage, obstetrical delivery, recent puncture of a non-compressible blood-vessel (e.g. subclavian or jugular vein puncture)
- •Chronic intoxication or chronic substance use disorder with pharmaceuticals, drugs, alcohol or industrial poisons
- •Symptoms of ischemic attack began more than 3 hours prior to start of thrombolytic therapy or if time of symptom onset is unknown
- •Minor neurological deficit or symptoms rapidly improving before start of infusion
- •Severe stroke as assessed clinically (e.g. NIHSS >25) and/or by appropriate
- •imaging techniques
- •Symptoms suggestive of subarachnoid haemorrhage, even if the CT-scan is normal
- •Known history of or suspected intracranial haemorrhage
- •Suspected subarachnoid haemorrhage or condition after subarachnoid hemorrhage from aneurysm
- •Any history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery)
- •Haemorrhagic retinopathy, e.g. in diabetes (vision disturbances may indicate haemorrhagic retinopathy)
- •Administration of heparin within the previous 48 hours and a thromboplastin time exceeding the upper limit of normal for laboratory
- •Patients receiving oral anticoagulants, e.g. warfarin sodium
- •Patients receiving Nifedipine for acute treatment
- •Special attention should be given to possible additive effects when used in conjunction with anti-depressants or MAO-inhibitors
- •Cerebrolysin should not be mixed with balanced amino acid solutions in an infusion
研究者
相似试验
进行中（未招募）
1 期
A prospective, randomised, placebo controlled, double blind trial about safety and efficacy of combined treatment with Alteplase (rt-PA) and Cerebrolysin(R) in acute ischemic hemispehric stroke - CERE-LYSE-1EUCTR2004-001729-11-SKEBEWE Pharma GesmbH Nfg.KG
进行中（未招募）
1 期
A prospective, randomised, placebo controlled, double blind trial about safety and efficacy of combined treatment with Alteplase (rt-PA) and Cerebrolysin(R) in acute ischemic hemispehric stroke - CERE-LYSE-1EUCTR2004-001729-11-CZEBEWE Pharma GesmbH Nfg.KG
进行中（未招募）
不适用
A prospective, randomised, placebo controlled, double blind trial about safety and efficacy of combined treatment with Alteplase (rt-PA) and Cerebrolysin in acute ischemic hemispheric stroke - CERE-LYSE-1EUCTR2004-001729-11-ATEBEWE Pharma Ges.m.b.H Nfg.KG108
进行中（未招募）
1 期
A prospective, randomised, placebo-controlled, double blind, multi-centre study of the effects of Irbesartan on aortic dilatation in Marfan syndromeMarfan SyndromeEUCTR2010-019302-16-GBRoyal Brompton and Harefield NHS Foundation Trust490
已完成
3 期
A prospective, randomized, placebo-controlled, double-blind, cross-over study of the usefulness of sustained-release opioids in the subjective sensation of dyspnoea secondary to advanced disease with no reversible components in opioid naive patients.Opioids in Refractory dyspnoeaRespiratory - Other respiratory disorders / diseasesACTRN12607000075482Repatriation General Hospital48